FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER (HER2+BC) PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS

被引：0
|
作者：
Bellone, M. [1 ]
Pradelli, L. [1 ]
Sanfilippo, A. [1 ]
Caputo, A. [2 ]
Manevy, M. [3 ]
Zerilli, A. [4 ]
机构：
[1] AdRes HEOR, Turin, TO, Italy
[2] Roche Spa, Monza, Italy
[3] F Hoffmann La Roche Ltd, Delemont, Switzerland
[4] Roche Spa, Milan, MI, Italy
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC113
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [1] A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer
    Ziegengeist, Julia L.
    Tan, Antoinette R.
    CLINICAL BREAST CANCER, 2025, 25 (02) : e124 - e132
  • [2] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach
    DuMond, Barbara
    Patel, Vidhi
    Gross, Anne
    Fung, Anita
    Weber, Susan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1214 - 1221
  • [3] Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)
    Gregori, Joaquin Gavila
    Miranda, Elena Lopez
    Escriva-de-Romani, Santiago
    Rodriguez, Begona Jimenez
    Novoa, Silvia Antolin
    Morales, Luis Fernandez
    Calvo, Elena Galve
    Cortijo, Lucia Gonzalez
    Martorell, Antonia Perello
    Ruiz, Julian Lagunar
    Santiago, Santiago Gonzalez
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer
    Swain, Sandra M.
    Tan, Antoinette R.
    Gianni, Luca
    Kuemmel, Sherko
    Dang, Chau T.
    Schneeweiss, Andreas
    O'Shaughnessy, Joyce
    Liu, Haiying
    Aguila, Christian
    Heeson, Sarah
    Macharia, Harrison
    Yang, Ke
    Restuccia, Eleonora
    Loibl, Sibylle
    EUROPEAN JOURNAL OF CANCER, 2023, 178 : 70 - 81
  • [5] Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)
    Swain, S. M.
    Tan, A.
    Gianni, L.
    Kummel, S.
    Dang, C.
    Schneeweiss, A.
    O'Shaughnessy, J.
    Liu, H.
    Aguila, C.
    Heeson, S.
    Macharia, H.
    Restuccia, E.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S419 - S420
  • [6] Cost minimization analysis of treatments for metastatic HER2-positive breast cancer in Peru: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injections
    Figallo, Miguel
    Delgado, Maria F.
    Gonzalez, Mauricio
    Arenas, Adrian
    PLOS ONE, 2024, 19 (11):
  • [7] Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
    Bei Wang
    Rong Deng
    Stefanie Hennig
    Tanja Badovinac Crnjevic
    Monika Kaewphluk
    Matts Kågedal
    Angelica L. Quartino
    Sandhya Girish
    Chunze Li
    Whitney P. Kirschbrown
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 499 - 512
  • [8] Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
    Bei Wang
    Rong Deng
    Stefanie Hennig
    Tanja Badovinac Crnjevic
    Monika Kaewphluk
    Matts Kågedal
    Angelica L. Quartino
    Sandhya Girish
    Chunze Li
    Whitney P. Kirschbrown
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 571 - 572
  • [9] Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
    Wang, Bei
    Deng, Rong
    Hennig, Stefanie
    Badovinac Crnjevic, Tanja
    Kaewphluk, Monika
    Kagedal, Matts
    Quartino, Angelica L.
    Girish, Sandhya
    Li, Chunze
    Kirschbrown, Whitney P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (03) : 499 - 512
  • [10] Subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of metastatic breast cancer in Canada - a budget impact analysis
    Sripada, Kaushik
    Manjrekar, Siddhi
    Klein-Panneton, Kristoph
    Coombes, Megan
    Ferrario, Cristiano
    CANCER RESEARCH, 2021, 81 (04)
12345